Exact Sciences

Walgreens Teams Up with Workflow Services and Exact Sciences to Expand Colorectal Cancer Screening Options

Privia Health

Exact Sciences' Colorectal Cancer Screening Initiative Sees Success, Undervalued Shares

Abbott Laboratories

Exact Sciences Shareholders Approve Merger with Abbott, Merger to Move Forward

Exact Sciences stockholders approve Abbott merger, reject executive pay proposal.

Abbott to raise $20B via bond sale for Exact Sciences acquisition

Catalyst<ul> <li>The recent MACD Golden Cross on March 20 suggests potential upward momentum for EXAS.</li> <li>All three active analysts rate EXAS as Strong Buy, indicating strong institutional confidence.</li></ul>Risk<ul> <li>Technical indicators show a volatile market with unclear direction, increasing uncertainty for EXAS.</li> <li>Fund flows show large and extra-large investors are net sellers, signaling potential bearish sentiment.</li></ul>

Key Factors

Abbott officially closes its $21 billion acquisition of Exact Sciences (EXAS) on March 23, 2026.

Recent Updates

EXAS News